An official website of the United States government
Home
Name
NKTR-214
Alternate Names
Bempegaldesleukin
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Melanoma
Remarks
8/2/2019 FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Coding
This drug should be coded
